Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia

详细信息查看全文

作者：Alison K McLean (1)
Cameron Stewart (2)
Ian Kerridge (2) (3) (4)

1. Sydney Medical School ; University of Sydney ; Edward Ford Building (A27) ; Fisher Road ; Sydney ; NSW ; 2206 ; Australia
2. Centre for Values ; Ethics and the Law in Medicine ; K25 ; Medical Foundation Building ; Sydney Medical School ; University of Sydney ; 92-94 Parramatta Road ; Camperdown ; NSW ; 2006 ; Australia
3. Haematology Department ; Royal North Shore Hospital ; St Leonards ; Sydney ; NSW ; 2065 ; Australia
4. Northern Blood Research Centre ; Kolling Institute ; Reserve Road ; St Leonards ; Sydney ; NSW ; 2065 ; Australia
刊名：Stem Cell Research & Therapy
出版年：2015
出版时间：December 2015
年：2015
卷：6
期：1
全文大小：69 KB
参考文献：1. National Health and Medical Research Council: / Stem Cell Treatments: A Quick Guide for Medical Practitioners. Canberra, Australia: National Health and Medical Research Council, Commonwealth of Australia, Canberra; 2013.
2. Copelan EA: Hematopoietic stem-cell transplantation.strong> / N Engl J Med 2006, 354:strong>1813鈥?826. 10.1056/NEJMra052638 CrossRef
3. Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, Dawn B: Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis.strong> / Circulation 2012, 126:strong>551鈥?68. 10.1161/CIRCULATIONAHA.111.086074 CrossRef
4. Boncoraglio GB, Bersano A, Candelise L, Reynolds BA, Parati EA: Stem cell transplantation for ischemic stroke.strong> / Cochrane Database Syst Rev 2010, 9:strong>CD007231.
5. Bura A, Planat-Benard V, Bourin P, Silvestre JS, Gross F, Grolleau JL, / et al.: Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia.strong> / Cytotherapy 2014, 16:strong>245鈥?57. 10.1016/j.jcyt.2013.11.011 CrossRef
6. Thomsen GM, Gowing G, Svendsen S, Svendsen C: The past, present and future of stem cell clinical trials for ALS.strong> / Exp Neurol 2014, 262PB:strong>127鈥?37. CrossRef
7. / A Single Centre Phase II Study of Hematopoietic Stem Cell transplantation (HSCT) for Severe Autoimmune Diseases, Trial ID: ACTRN12613000339752. stration/TrialReview.aspx?id=363746&isClinicalTrial=False" class="a-plus-plus">https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363746&isClinicalTrial=False
8. Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, / et al.: Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial.strong> / Stem Cells 2014, 32:strong>1254鈥?266. 10.1002/stem.1634 stem.1634" target="_blank" title="It opens in new window">CrossRef
9. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M: The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials.strong> / Ann Rheum Dis 2008, 67:strong>1716鈥?723. 10.1136/ard.2008.092015 CrossRef
10. Sipp D: The unregulated commercialization of stem cell treatments: a global perspective.strong> / Front Med 2011, 5:strong>348鈥?55. 10.1007/s11684-011-0150-x CrossRef
11. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, / et al.: Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials.strong> / PLoS One 2012, 7:strong>1932鈥?203. CrossRef
12. Minguell JJ, Allers C, Lasala GP: Mesenchymal stem cells and the treatment of conditions and diseases: the less glittering side of a conspicuous stem cell for basic research.strong> / Stem Cells Dev 2013, 22:strong>193鈥?03. 10.1089/scd.2012.0417 CrossRef
13. Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, / et al.: Defining the risks of mesenchymal stromal cell therapy.strong> / Cytotherapy 2010, 12:strong>576鈥?78. 10.3109/14653249.2010.507330 CrossRef
14. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, / et al.: Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient.strong> / PLoS Med 2009, 6:strong>e1000029. CrossRef
15. Dloughy B, Awe O, Rao R, Kirby P, Hitchon P: Autolograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient.strong> / J Neurosurg Spine 2014, 21:strong>618鈥?22. 10.3171/2014.5.SPINE13992 CrossRef
16. Thirabanjasak D, Tantiwongse K, Thorner P: Angiomyeloproliferative lesions following autologous stem cell therapy.strong> / J Am Soc Nephrol 2010, 21:strong>1218鈥?222. 10.1681/ASN.2009111156 CrossRef
17. Jung JW, Kwon M, Choi JC, Shin JW, Park IW, Choi BW, / et al.: Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy.strong> / Yonsei Med J 2013, 54:strong>1293鈥?296. 10.3349/ymj.2013.54.5.1293 CrossRef
18. Pytel P, Husain A, Moskowitz I, Raman J, MacLeod H, Anderson AS, / et al.: Ventricular fibrillation following autologous intramyocardial cell therapy for inherited cardiomyopathy.strong> / Cardiovasc Pathol 2010, 19:strong>e33-e6. 10.1016/j.carpath.2008.09.004 CrossRef
19. Kishk N, Abokrysha N, Gabr H: Possible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injection.strong> / J Clin Neurosci 2013, 20:strong>310鈥?12. 10.1016/j.jocn.2012.04.013 CrossRef
20. Bright R: Adipose derived stromal cells to treat joint disease.strong> / Journal of Cosmetic Surgery and Medicine 2010, 5:strong>62鈥?4.
21. Macquarie Stem Cells: / Stem cell treatment for osteoarthritis. stemcells.com/stem-cell-therapy-for-osteoarthritis" class="a-plus-plus">http://www.macquariestemcells.com/stem-cell-therapy-for-osteoarthritis
22. Ltd R: / Osteoarthritis Stem Cell Advanced Research Study (OSCARS) Interim Report: A Randomised Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Autologous Non-expanded Adipose-derived Stem Cells in the Treatment of Knee Osteoarthritis. Sydney, Australia: Regeneus Ltd; 2013.
23. Gardner P: / Stem cells to treat osteoarthritis. Today Tonight 19 October 2012 [https://www.youtube.com/watch?v=0wx0affwTgc]
24. Hansen D: / Stem cell treatment. Today Tonight 20 August 2013 [stemcellclinic.net/tag/damien-hansen" class="a-plus-plus">http://www.stemcellclinic.net/tag/damien-hansen]
25. Polkinghorne L: / Arthritis stem cell treatment. Today Tonight Adelaide 24 June 2013 [stories/arthritis-stem-cell-treatment" class="a-plus-plus">http://www.todaytonightadelaide.com.au/stories/arthritis-stem-cell-treatment]
26. Sparkes L: / Arthritis breakthrough. Today Tonight 25 November 2011 [stories/arthritis-lipo" class="a-plus-plus">http://www.todaytonightadelaide.com.au/stories/arthritis-lipo]
27. Brockie J: / Stem cells. Insight 15 July 2014 [stem-cells" class="a-plus-plus">http://www.sbs.com.au/news/insight/tvepisode/stem-cells]
28. Aubusson K: A therapy for autism?strong> / Australian Doctor 2014.
29. Macquarie Stem Cells: / Disclaimer. stemcells.com" class="a-plus-plus">http://www.macquariestemcells.com
30. Brisbane Regeneration: / Media centre. http://www.brisbaneregeneration.com.au/media-centre
31. Stem Cell Solutions: / Adverse effects. stemcellsolutions.com.au/wp-content/uploads/2012/12/stem-cell-information.pdf" class="a-plus-plus">http://www.stemcellsolutions.com.au/wp-content/uploads/2012/12/stem-cell-information.pdf
32. National Health and Medical Research Council: / NHMRC Warns of the Risks Associated with Unproven Stem Cell Therapies in Australia and Overseas. Canberra, Australia: National Health and Medical Research Council; 2013.
33. Norwood Day Surgery: / Osteoarthritis treatment options. steoarthritis-treatment-options" class="a-plus-plus">http://www.norwooddaysurgery.com.au/osteoarthritis-treatment-options
34. Stem Cell Solutions: / Osteoarthritis treatment. stemcellsolutions.com.au/wp-content/uploads/2012/12/Osteoarthritis-Treatment.pdf" class="a-plus-plus">http://www.stemcellsolutions.com.au/wp-content/uploads/2012/12/Osteoarthritis-Treatment.pdf
35. Macquarie Stem Cells: / Benefits of stem cell therapy. stemcells.com/benefits-stem-cell-therapy" class="a-plus-plus">http://www.macquariestemcells.com/benefits-stem-cell-therapy
36. Autologous Stem Cell Technology: / Technology. - technology http://asctech.com.au/index.html
37. / Stem cells for Josh. stemcellsforjosh?fref=ts" class="a-plus-plus">https://www.facebook.com/stemcellsforjosh?fref=ts
38. Therapeutic Goods Administration: / What the TGA regulates. http://www.tga.gov.au/about/tga-regulates-what.htm
39. Therapeutic Goods Administration: / Therapeutic Goods (Excluded Goods) Order No. 1 of 2011. 2011.
40. Australian Medical Council: / Good Medical Practice: A Code of Conduct for Doctors in Australia. Kingston, Australia: Australian Medical Council; 2014.
41. Parliament of New South Wales, Australia: / Health Practitioner Regulation National Law (NSW) Act (NSW) 2009, ss139B and 139E.
42. Kerridge I, Lowe M, Stewart C: / Ethics and Law for the Health Professions. 4th edition. Annandale, Australia: The Federation Press; 2013.
43. Australian Competition and Consumer Commission: / Medical professionals. http://www.accc.gov.au/business/professional-services/medical-professionals
44. Commonwealth Parliament of Australia: / Competition and Consumer Act 2010 (Cth). 2010, s29.
45. Australian Competition and Consumer Commission: / False or misleading claims. http://www.accc.gov.au/consumers/misleading-claims-advertising/false-or-misleading-claims
46. Cowan D: Innovative therapy versus experimentation.strong> / Tort Insur Law J 1986, 21:strong>619鈥?33.
47. National Health and Medical Research Council and the Australian Research Council: / National Statement on Ethical Conduct in Human Research. Canberra, Australia: National Health and Medical Research Council and the Australian Research Council, Commonwealth of Australia, Canberra; 2007.
48. Chan TE: Legal and regulatory responses to innovative treatment.strong> / Med Law Rev 2013, 21:strong>92鈥?30. 10.1093/medlaw/fws025 CrossRef
49. Taylor PL: Overseeing innovative therapy without mistaking it for research: a function-based model based on old truths, new capacities, and lessons from stem cells.strong> / J Law Med Ethics 2010, 38:strong>286鈥?02. 10.1111/j.1748-720X.2010.00489.x CrossRef
50. Healey P, Samanta J: When does the 鈥榣earning curve鈥?of innovative interventions become questionable practice?strong> / Eur J Vasc Endovasc Surg 2008, 36:strong>1532鈥?165. CrossRef
51. Insoo H: Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges.strong> / J Law Med Ethics 2010, 38:strong>277鈥?85. 10.1111/j.1748-720X.2010.00488.x CrossRef
52. Strasberg S, Ludbrook P: Who oversees innovative practice? Is there a structure that meets the monitoring needs of new techniques?strong> / J Am Coll Surg 2003, 196:strong>938鈥?48. 10.1016/S1072-7515(03)00112-1 CrossRef
53. Barkun JS, Aronson JK, Feldman LS, Maddern GJ, Strasberg SM, Altman DG, / et al.: Evaluation and stages of surgical innovations.strong> / Lancet 2009, 374:strong>1089鈥?096. 10.1016/S0140-6736(09)61083-7 CrossRef
54. Lewens T: Distinguishing treatment from research: a functional approach.strong> / J Med Ethics 2006, 32:strong>424鈥?29. 10.1136/jme.2005.013078 CrossRef
55. Munsie M, Hyun I: A question of ethics: selling autologous stem cell therapies flaunts professional standards.strong> / Stem Cell Res 2014, 13:strong>647鈥?53. 10.1016/j.scr.2014.04.014 CrossRef
56. International Society for Stem Cell Research: / Guidelines for the Clinical Translation of Stem Cells. Skokie, IL: International Society for Stem Cell Research; 2008.
57. McLean AK, Stewart C, Kerridge I: The emergence and popularisation of autologous somatic cellular therapies in Australia: therapeutic innovation or regulatory failure?strong> / Journal of Law and Medicine 2014,22strong>(1):strong>65鈥?9.
58. Scott S, Branley A: Stem cell warning: experts fear experimental treatments will lead to serious injury.strong> / ABC News 2013.
59. Kirsten AR, Amanda NS, Dong DW, Aaron DL: Tracking the rise of stem cell tourism.strong> / Regen Med 2010, 5:strong>27鈥?3. 10.2217/rme.09.70 CrossRef
60. Australian Health Practitioner Regulation Agency: / Guidelines for Advertising Regulated Health Services. Melbourne, Australia: Australian Health Practitioner Regulation Agency; 2014.
61. Health Practitioner Regulation National Law, s133 (c): / Australian Health Practitioner Regulation Agency Guidelines for Advertising Regulated Health Services, section 6.2, May 2014. Melbourne, Australia: Australian Health Practitioner Regulation Agency; 2009.
62. Medical Board of Australia, Good Medical Practice: / A Code of Conduct for Doctors in Australia. Section 8.6.4. Melbourne, Australia: Medical Board of Australia; 2014.
63. Taylor PL, Barker RA, Blume KG, Cattaneo E, Colman A, Deng H, / et al.: Patients beware: commercialized stem cell treatments on the web.strong> / Cell Stem Cell 2010, 7:strong>43鈥?9. 10.1016/j.stem.2010.06.001 stem.2010.06.001" target="_blank" title="It opens in new window">CrossRef
64. Main H, Munsie M, O鈥機onnor MD: Managing the potential and pitfalls during clinical translation of emerging stem cell therapies.strong> / Clin Transl Med 2014, 3:strong>10. 10.1186/2001-1326-3-10 CrossRef
65. Parliament of New South Wales, Australia: / Health Practitioner Regulation National Law. Section 133. 2009.
66. ustralian Health Practitioner Regulation Agency: / Guidelines for Advertising Regulated Health Services. Sections 6.1, 6.2, 7.4, and 7.6. Melbourne, Australia: Australian Health Practitioner Regulation Agency; 2014.
67. Medical Board of Australia, Good Medical Practice: / A Code of Conduct for Doctors in Australia. Sections 8.6 and 8.9. Melbourne, Australia: Medical Board of Australia; 2014.
68. Lindvall O, Hyun I: Medical innovation versus stem cell tourism.strong> / Science 2009, 324:strong>1664鈥?665. 10.1126/science.1171749 CrossRef
69. Qiu J: Trading on hope.strong> / Nat Biotechnol 2009, 27:strong>790鈥?92. 10.1038/nbt0909-790 CrossRef
70. Lau D, Ogbogu U, Taylor B, Stafinski T, Menon D, Caulfield T: Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine.strong> / Cell Stem Cell 2008, 3:strong>591鈥?94. 10.1016/j.stem.2008.11.001 stem.2008.11.001" target="_blank" title="It opens in new window">CrossRef
71. Zarzeczny A, Rachul C, Nisbet M, Caulfield T: Stem cell clinics in the news.strong> / Nat Biotechnol 2010, 28:strong>1243鈥?246. CrossRef
刊物主题：Stem Cells; Cell Biology;
出版者：BioMed Central
ISSN：1757-6512

文摘

An increasing number of private clinics in Australia are marketing and providing autologous stem cell therapies to patients. Although advocates point to the importance of medical innovation and the primacy of patient choice, these arguments are unconvincing. First, it is a stark truth that these clinics are flourishing while the efficacy and safety of autologous stem cell therapies, outside of established indications for hematopioetic stem cell transplantation, are yet to be shown. Second, few of these therapies are offered within clinical trials. Third, patients with chronic and debilitating illnesses, who are often the ones who take up these therapies, incur significant financial burdens in the expectation of benefiting from these treatments. Finally, the provision of these stem cell therapies does not follow the established pathways for legitimate medical advancement. We argue that greater regulatory oversight and professional action are necessary to protect vulnerable patients and that at this time the provision of unproven stem cell therapies outside of clinical trials is unethical.